TLDR
- Cardinal Health shares surge 9% following an earnings beat and upgraded outlook
- Revenue grows 19% as the specialty segment fuels profit expansion
- A $750M buyback reduces share count and enhances EPS momentum
- Segment profits jump significantly due to scale and cost control
- FY26 guidance is raised with double-digit earnings growth projected ahead
Cardinal Health (CAH) shares saw a sharp rise, trading at $225.88—a 9.20% increase—signaling robust momentum post a strong earnings announcement. The company reported broad improvements in revenue, earnings, and segment performance, while also strengthening its fiscal 2026 outlook. Market reaction was driven by the upgraded guidance and the completion of a $750 million buyback, reflecting renewed confidence in operational execution.
Stronger Q2 Results Drive Upward Shift
Cardinal Health reported second-quarter revenue of $65.6 billion, marking a 19% year-over-year increase. GAAP operating earnings came in at $707 million, up 29%. Non-GAAP operating earnings reached $877 million, reflecting a 38% expansion alongside a lower share count.
The company posted GAAP diluted EPS of $1.97, while non-GAAP diluted EPS hit $2.63. Growth stemmed from higher operating earnings, though financing costs from recent acquisitions partially tempered this strength. Net earnings attributable to the company stood at $467 million, with non-GAAP net earnings at $624 million.
Cardinal Health completed its annual baseline share repurchase of $750 million, reducing the diluted share count. The company also achieved its targeted leverage range, supporting its enhanced capital deployment strategy. Second-quarter results underscored ongoing operational discipline, with momentum sustained across all reporting segments.
Segment Gains Reinforce Execution Strength
The Pharmaceutical and Specialty Solutions segment generated $60.7 billion in revenue, a 19% increase driven by growing customer activity. Segment profit rose 29% to $687 million, bolstered by contributions from specialty products and MSO acquisitions. The generics program provided additional support, with performance aligning with rising demand for brand products.
The Global Medical Products and Distribution segment recorded $3.3 billion in revenue, a 3% increase due to higher customer volumes. Segment profit improved 106% to $37 million, supported by cost optimization initiatives. Tariff impacts partially offset these gains, though the segment maintained strong operational efficiency.
Other revenue reached $1.7 billion, advancing 34% on growth across at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics. Segment profit rose 52% to $179 million, driven by scale benefits. The acquisition of Advanced Diabetes Supply expanded the portfolio, with demand strengthening across multiple channels.
FY26 Outlook Raised as Strategic Plans Advance
Cardinal Health raised its fiscal 2026 non-GAAP EPS guidance to $10.15–$10.35, representing 23%–26% growth. The Pharmaceutical and Specialty Solutions segment profit outlook was lifted to 20%–22%, reflecting sustained strength in specialty markets. The Global Medical Products and Distribution segment profit target increased to approximately $150 million, while the Other segment profit growth outlook rose to 33%–35%.
The company also lowered its non-GAAP effective tax rate outlook to 21%–23%, supporting its profitability goals. Diluted weighted average shares decreased to a range of 237 million–238 million, following continued buybacks. Management highlighted new MSO acquisitions, expanded at-Home offerings, and cultural certifications as key milestones.
Cardinal Health completed an additional $375 million accelerated repurchase program in the quarter, bringing year-to-date repurchases to $750 million. The Specialty Alliance finalized the acquisition of Solaris Health, strengthening its multi-specialty MSO footprint. The company also advanced diabetes support programs and formed new retail partnerships, expanding its patient access strategy.
